Infantile hemangioma. Part 2: Management.
Sebaratnam DF, Rodríguez Bandera AL, Wong LF, Wargon O.
J Am Acad Dermatol. 2021 Dec;85(6):1395-1404. doi: 10.1016/j.jaad.2021.08.020. Epub 2021 Aug 19.
LncRNA NEAT1 Regulates Infantile Pneumonia by Sponging miR-146b.
Cui J, Wang J, Lv Y, Xu D.
Mol Biotechnol. 2021 Aug;63(8):694-701. doi: 10.1007/s12033-021-00331-w. Epub 2021 May 12.
Management of Neurological Emergencies in Children: An Updated Overview.
Mastrangelo M, Baglioni V.
Neuropediatrics. 2021 Aug;52(4):242-251. doi: 10.1055/s-0041-1730936. Epub 2021 Jun 30.
Twist2 Reduced NLRP3-Induced Inflammation of Infantile Pneumonia via Regulation of Mitochondrial Permeability Transition by FOXO1.
Ding N, Liu D, Duan X, Zhang J, Ma S, Chen Y.
Int Arch Allergy Immunol. 2022;183(10):1098-1113. doi: 10.1159/000525063. Epub 2022 Jun 14.
Sphingosine Kinase-1 (SPHK1) promotes inflammation in infantile pneumonia by regulating NLRP3 inflammasome and SIRT1 expression.
Ding N, Meng Y, Liu L, Ma S, Chen Y.
Histol Histopathol. 2022 Dec;37(12):1227-1240. doi: 10.14670/HH-18-491. Epub 2022 Jul 7.
Etiology of molar incisor hypomineralization - A systematic review.
Silva MJ, Scurrah KJ, Craig JM, Manton DJ, Kilpatrick N.
Community Dent Oral Epidemiol. 2016 Aug;44(4):342-53. doi: 10.1111/cdoe.12229. Epub 2016 Apr 28.
Circ_0026579 alleviates LPS-induced WI-38 cells inflammation injury in infantile pneumonia.
Yu Y, Yang T, Ding Z, Cao Y.
Innate Immun. 2022 Jan;28(1):37-48. doi: 10.1177/17534259211069104.
miRNA-302e attenuates inflammation in infantile pneumonia though the RelA/BRD4/NF-kappaB signaling pathway.
Li S, Cui W, Song Q, Zhou Y, Li J.
Int J Mol Med. 2019 Jul;44(1):47-56. doi: 10.3892/ijmm.2019.4194. Epub 2019 May 10.
Infantile Anti-N-Methyl-D-Aspartate Receptor Encephalitis Post-SARS-CoV-2 Infection.
Kaur P, Vinay MV, Madarkar BS.
Indian Pediatr. 2022 Apr 15;59(4):343-344. doi: 10.1007/s13312-022-2506-5.
Caractéristiques des hospitalisations au Canada d’enfants ayant contracté une infection aiguë par le SRAS-CoV-2 en 2020.
Drouin O, Hepburn CM, Farrar DS, Baerg K, Chan K, Cyr C, Donner EJ, Embree JE, Farrell C, Forgie S, Giroux R, Kang KT, King M, Laffin M, Luu TM, Orkin J, Papenburg J, Pound CM, Price VE, Purewal R, Sadarangani M, Salvadori MI, Top KA, Viel-Thériault I, Kakkar F, Morris SK; pour l’équipe de l’étude sur la COVID-19 du Programme canadien de surveillance pédiatrique.
CMAJ. 2021 Nov 22;193(46):E1774-E1785. doi: 10.1503/cmaj.210053-f.
